for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merrimack Pharmaceuticals Inc

MACK.O

Latest Trade

4.56USD

Change

0.00(0.00%)

Volume

3

Today's Range

--

 - 

--

52 Week Range

3.56

 - 

9.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.56
Open
0.00
Volume
3
3M AVG Volume
0.48
Today's High
--
Today's Low
--
52 Week High
9.45
52 Week Low
3.56
Shares Out (MIL)
13.41
Market Cap (MIL)
61.15
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2021 Merrimack Pharmaceuticals Inc Earnings Release

Latest Developments

More

Merrimack Pharmaceuticals Q2 Loss Per Share $0.06

Merrimack Pharmaceuticals Q3 Loss Per Share $0.08

Merrimack Reports Q2 Loss Per Share Of $0.09

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is entitled to receive contingent milestone payments related to its sale of ONIVYDE to Ipsen S.A. ONIVYDE is approved by the Unites States Food and Drug Administration (FDA) in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets.

Industry

Biotechnology & Drugs

Contact Info

1 Broadway Fl 14

CAMBRIDGE, MA

02142-1187

United States

+1.617.4411000

https://www.merrimack.com/

Executive Leadership

Gary L. Crocker

Chairman of the Board, President, Treasurer

Eric D. Andersen

Independent Director

Noah G. Levy

Independent Director

Ulrik B. Nielsen

Independent Director

Russell T. Ray

Independent Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.05
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-22.01
Return on Equity (TTM)
-20.08

Latest News

Latest News

Ex-Akebia, Merrimack employees' insider trading convictions stand

The 1st U.S. Circuit Court of Appeals on Friday upheld the convictions and prison sentences of former Akebia Therapeutics Inc and Merrimack Pharmaceuticals Inc employees who were found to have taken part in an insider trading scheme.

BRIEF-Merrimack Reports First Quarter 2020 Financial Results

* AS OF MARCH 31, HAD CASH AND CASH EQUIVALENTS AND INVESTMENTS OF $18.0 MILLION Source text for Eikon: Further company coverage:

BRIEF-Merrimack Divests Early Stage Asset For $2.25 Mln Provides Strategy Update

* MERRIMACK DIVESTS EARLY STAGE ASSET FOR $2.25 MILLION; PROVIDES STRATEGY UPDATE

BRIEF-Merrimack Pharmaceuticals Entered Into An Asset Purchase Agreement With Celator Pharmaceuticals, Inc.

* MERRIMACK PHARMACEUTICALS INC - ENTERED INTO AN ASSET PURCHASE AGREEMENT WITH CELATOR PHARMACEUTICALS, INC.

Ex-Merrimack Pharmaceuticals employee gets prison for insider trading

A former Merrimack Pharmaceuticals Inc employee was sentenced on Tuesday to six months in prison after being convicted of participating in an insider trading scheme with a friend at a rival biopharmaceutical company.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up